Online inquiry

IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1517MR)

This product GTTS-WQ1517MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets INHBA gene. The antibody can be applied in Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002192.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3624
UniProt ID P08476
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ1517MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2837MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG-403
GTTS-WQ14822MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-75
GTTS-WQ4655MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986036
GTTS-WQ6930MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ENIA11
GTTS-WQ7228MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ4836MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BT-062
GTTS-WQ5987MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 095
GTTS-WQ3860MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BCD-089
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW